Skip to main content

14.08.2019 | Reviews

Effect of antithrombotic drugs on bone health

verfasst von: G. Dadwal, T. Schulte-Huxel, G. Kolb

Erschienen in: Zeitschrift für Gerontologie und Geriatrie

Einloggen, um Zugang zu erhalten

Abstract

With the increasing consumption of antithrombotic drugs among old people, expected as well as unexpected side effects on bone health are considerable, e.g. osteoporosis, fragility fractures, etc. This review focuses on antithrombotic drugs and their effects on bone health. The following groups were reviewed: parenteral long-term use of unfractionated heparin (UFH) is associated with osteopenia. The oral intake of vitamin K antagonists (VKA) makes them more convenient than UFH but chronic use also results in osteopenia. Limited reports of bone loss have been associated with low molecular weight heparins (LMWH) and indirect factor Xa inhibitors but in contrast to VKA and UFH they are less associated with osteopenia. There have been limited studies evaluating the effect of new oral anticoagulants (NOACs) on bones. Overall, they are considered safer than other drugs. There have been no reports about acetylsalicylic acid (ASA) and clopidogrel causing osteopenia but their metabolism by the kidneys and liver can cause reduced 25-hydroxy-vitamin D levels and can theoretically contribute to osteoporosis. Some reports suggested that high dosage clopidogrel can also negatively affect bones. After a detailed literature review long-term use of antithrombotic drugs can negatively affect the bones. Their role in bone health needs to be studied in detail and the clinical use in geriatric patients should be prudent.
Literatur
4.
Zurück zum Zitat Bauer DC, Orwoll ES, Fox KM, Vogt TM, Lane NE, Hochberg MC, Stone K, Nevitt MC (1996) Aspirin and NSAID use in older women: effect on bone mineral density and fracture risk. Study of Osteoporotic Fractures Research Group. J Bone Miner Res 11(1):29–35PubMedCrossRef Bauer DC, Orwoll ES, Fox KM, Vogt TM, Lane NE, Hochberg MC, Stone K, Nevitt MC (1996) Aspirin and NSAID use in older women: effect on bone mineral density and fracture risk. Study of Osteoporotic Fractures Research Group. J Bone Miner Res 11(1):29–35PubMedCrossRef
6.
Zurück zum Zitat Hulisz D (2006) Drug-induced osteoporosis, effects of medications on bone density. Us Pharm 12:HS3–HS6 Hulisz D (2006) Drug-induced osteoporosis, effects of medications on bone density. Us Pharm 12:HS3–HS6
7.
Zurück zum Zitat Gage BF, Birman-Deych E, Radford MJ, Nilasena DS, Binder EF (2006) Risk of osteoporotic fracture in elderly patients taking warfarin: results from the National Registry of Atrial Fibrillation 2. Arch Intern Med 166(2):241–246PubMedCrossRef Gage BF, Birman-Deych E, Radford MJ, Nilasena DS, Binder EF (2006) Risk of osteoporotic fracture in elderly patients taking warfarin: results from the National Registry of Atrial Fibrillation 2. Arch Intern Med 166(2):241–246PubMedCrossRef
10.
Zurück zum Zitat Griffith GC, Nichols G Jr., Asher JD et al (1965) Heparin Osteoporosis. JAMA 193(2):91–94PubMedCrossRef Griffith GC, Nichols G Jr., Asher JD et al (1965) Heparin Osteoporosis. JAMA 193(2):91–94PubMedCrossRef
11.
Zurück zum Zitat Hak DJ, Stewart RL, Hazelwood SJ (2006) Effect of low molecular weight heparin on fracture healing in a stabilized rat femur fracture model. J Orthop Res 24(4):645–652PubMedCrossRef Hak DJ, Stewart RL, Hazelwood SJ (2006) Effect of low molecular weight heparin on fracture healing in a stabilized rat femur fracture model. J Orthop Res 24(4):645–652PubMedCrossRef
12.
Zurück zum Zitat Handschin AE, Trentz OA, Hoerstrup SP, Kock HJ, Wanner GA, Trentz O (2005) Effect of low molecular weight heparin and Fondaparinux on human osteonblasts in vitro. Br J Surg 92(2):177–183PubMedCrossRef Handschin AE, Trentz OA, Hoerstrup SP, Kock HJ, Wanner GA, Trentz O (2005) Effect of low molecular weight heparin and Fondaparinux on human osteonblasts in vitro. Br J Surg 92(2):177–183PubMedCrossRef
15.
Zurück zum Zitat Kock HJ, Werther S, Uhlenkott H, Taeger G (2002) Influence of unfractionated and low-molecular-weight heparin on bone healing: an animal model. Unfallchirurg 105(9):791–796PubMedCrossRef Kock HJ, Werther S, Uhlenkott H, Taeger G (2002) Influence of unfractionated and low-molecular-weight heparin on bone healing: an animal model. Unfallchirurg 105(9):791–796PubMedCrossRef
17.
18.
Zurück zum Zitat Laura S. Lehman, PharmD; Does Warfarin Use Affect Bone Health? Laura S. Lehman, PharmD; Does Warfarin Use Affect Bone Health?
20.
Zurück zum Zitat Namba S, Yamaoka Tojo M, Kakizaki R, Nemoto T, Fujiyoshi K, Hashikata T, Kitasato L, Hashimoto T, Kameda R, Meguro K, Shimohama T, Tojo T, Ako J (2017) Effects on bone metabolism markers and arterial stiffness by switching to rivaroxaban from warfarin in patients with atrial fibrillation. Heart Vessels 32(8):977–982. https://doi.org/10.1007/s00380-017-0950-2PubMedCrossRef Namba S, Yamaoka Tojo M, Kakizaki R, Nemoto T, Fujiyoshi K, Hashikata T, Kitasato L, Hashimoto T, Kameda R, Meguro K, Shimohama T, Tojo T, Ako J (2017) Effects on bone metabolism markers and arterial stiffness by switching to rivaroxaban from warfarin in patients with atrial fibrillation. Heart Vessels 32(8):977–982. https://​doi.​org/​10.​1007/​s00380-017-0950-2PubMedCrossRef
22.
Zurück zum Zitat Pietschmann P, Woloszczuk WS, Panzer S, Kyrle P, Smolen J (1988) Decreased serum osteocalcin levels in Phenprocoumon-treated patients. J Clin Endocrinol Metab 66(5):1071–1074PubMedCrossRef Pietschmann P, Woloszczuk WS, Panzer S, Kyrle P, Smolen J (1988) Decreased serum osteocalcin levels in Phenprocoumon-treated patients. J Clin Endocrinol Metab 66(5):1071–1074PubMedCrossRef
23.
Zurück zum Zitat Resch H, Pietschmann P, Krexner E, Woloszczuk W, Willvonseder R (1991) Decreased peripheral bone mineral content in patients under anticoagulant therapy with phenprocoumon. Eur Heart J 12(3):439–441PubMedCrossRef Resch H, Pietschmann P, Krexner E, Woloszczuk W, Willvonseder R (1991) Decreased peripheral bone mineral content in patients under anticoagulant therapy with phenprocoumon. Eur Heart J 12(3):439–441PubMedCrossRef
27.
Zurück zum Zitat Street JT, McGrath M, O’Regan K et al (2000) Thromboprophylaxis using a low molecular weight heparin delays fracture repair. Clin Orthop Relat Res 381:278–289CrossRef Street JT, McGrath M, O’Regan K et al (2000) Thromboprophylaxis using a low molecular weight heparin delays fracture repair. Clin Orthop Relat Res 381:278–289CrossRef
28.
Zurück zum Zitat Syberg S, Brandao-Burch A, Patel JJ, Hajjawi M, Arnett TR, Schwarz P et al (2012) Clopidogrel (Plavix), a P2Y12 receptor antagonist, inhibits bone cell function in vitro and decreases trabecular bone in vivo. J Bone Miner Res 27(11):2373–2386. https://doi.org/10.1002/jbmr.1690PubMedCrossRef Syberg S, Brandao-Burch A, Patel JJ, Hajjawi M, Arnett TR, Schwarz P et al (2012) Clopidogrel (Plavix), a P2Y12 receptor antagonist, inhibits bone cell function in vitro and decreases trabecular bone in vivo. J Bone Miner Res 27(11):2373–2386. https://​doi.​org/​10.​1002/​jbmr.​1690PubMedCrossRef
Metadaten
Titel
Effect of antithrombotic drugs on bone health
verfasst von
G. Dadwal
T. Schulte-Huxel
G. Kolb
Publikationsdatum
14.08.2019
Verlag
Springer Medizin
Erschienen in
Zeitschrift für Gerontologie und Geriatrie
Print ISSN: 0948-6704
Elektronische ISSN: 1435-1269
DOI
https://doi.org/10.1007/s00391-019-01590-8